[pubmed] Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder canc

Verrouillé
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6501
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[pubmed] Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder canc

Message par RSS-Bot »


IJU Case Rep. 2019 Oct 30;3(1):17-20. doi: 10.1002/iju5.12128. eCollection 2020 Jan.

ABSTRACT

INTRODUCTION: Pembrolizumab cause immune-related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course.

CASE PRESENTATION: A 63-year-old man with bladder carcinoma was treated by radical cystectomy, however, the bladder carcinoma recurred and invaded to the rectum. He was treated by combination therapy using gemcitabine and cisplatin, which were not effective for the tumor. He subsequently underwent treatment with pembrolizumab. In several 30 days, he suffered from the symptoms of myasthenia gravis. Serum levels of creatine kinase, its isozyme creatine kinase-myocardial band, and troponin I were elevated. Electrocardiography showed a right bundle branch block. These findings suggested that he was myasthenia gravis with general myositis and presumable myocarditis. Oral prednisolone administration significantly attenuated these findings. The tumor drastically shrunk only by the single injection of pembrolizumab.

CONCLUSION: Early intervention with corticosteroid was effective for neuromuscular complications due to pembrolizumab.

PMID:32743459 | PMC:PMC7292166 | DOI:10.1002/iju5.12128


Source: https://pubmed.ncbi.nlm.nih.gov/3274345 ... 6&v=2.11.4
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Verrouillé

Retourner vers « Echos de la recherche »